(Q36811131)

16 August 2017

1 reference

title

Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists (English)

1 reference

16 August 2017

0 references

0 references

Holger Kanzler

1

1 reference

16 August 2017

Franck J Barrat

series ordinal

2

1 reference

16 August 2017

Edith M Hessel

series ordinal

3

1 reference

16 August 2017

Robert L Coffman

series ordinal

4

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 May 2007

1 reference

16 August 2017

1 reference

16 August 2017

13

1 reference

16 August 2017

5

1 reference

16 August 2017

552-559

1 reference

https://scigraph.springernature.com/pub.10.1038/nm1589

16 August 2017

0 references

cites work

Human TLR10 is a functional receptor, expressed by B cells and plasmacytoid dendritic cells, which activates gene transcription through MyD88

1 reference

Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles

21 January 2018

1 reference

TLR3 can directly trigger apoptosis in human cancer cells.

21 January 2018

1 reference

How the immune system works to protect the host from infection: a personal view

21 January 2018

1 reference

7 January 2021

Innate immune recognition

1 reference

7 January 2021

The innate signaling of dangers and the dangers of innate signaling

1 reference

7 January 2021

Intracellular pattern recognition receptors in the host response

1 reference

7 January 2021

Pathogen recognition and innate immunity

1 reference

7 January 2021

TLR signaling pathways: opportunities for activation and blockade in pursuit of therapy

1 reference

7 January 2021

The dorsoventral regulatory gene cassette spätzle/Toll/cactus controls the potent antifungal response in Drosophila adults

1 reference

7 January 2021

The immune response of Drosophila

1 reference

7 January 2021

A human homologue of the Drosophila Toll protein signals activation of adaptive immunity

1 reference

7 January 2021

The evolution of vertebrate Toll-like receptors

1 reference

7 January 2021

A family of human receptors structurally related to Drosophila Toll

1 reference

7 January 2021

Genomic insights into the immune system of the sea urchin

1 reference

7 January 2021

Crystal structure of human toll-like receptor 3 (TLR3) ectodomain

1 reference

7 January 2021

The molecular structure of the Toll-like receptor 3 ligand-binding domain.

1 reference

7 January 2021

Recognition of pathogen-associated molecular patterns by TLR family

1 reference

7 January 2021

TLR9 signals after translocating from the ER to CpG DNA in the lysosome

1 reference

7 January 2021

Maintenance of colonic homeostasis by distinctive apical TLR9 signalling in intestinal epithelial cells

1 reference

7 January 2021

Toll-like receptor signalling

1 reference

7 January 2021

Toll-like receptors in systemic autoimmune disease

1 reference

7 January 2021

Therapeutic potential of Toll-like receptor 9 activation

1 reference

7 January 2021

Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: Activation of Toll-like receptor 7

1 reference

7 January 2021

Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529.

1 reference

7 January 2021

Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3

1 reference

7 January 2021

Toll-like receptors as molecular switches.

1 reference

7 January 2021

TLR signalling and activation of IRFs: revisiting old friends from the NF-kappaB pathway

1 reference

7 January 2021

Type I interferons in host defense

1 reference

7 January 2021

Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors

1 reference

7 January 2021

Toll-like receptor control of the adaptive immune responses

1 reference

7 January 2021

Toll-like receptors stimulate human neutrophil function

1 reference

7 January 2021

Lymphocyte trafficking and regional immunity.

1 reference

7 January 2021

Limiting inflammatory responses during activation of innate immunity

1 reference

7 January 2021

Translating innate immunity into immunological memory: implications for vaccine development

1 reference

7 January 2021

Dendritic cells and the control of immunity

1 reference

7 January 2021

Innate immune recognition of viral infection

1 reference

7 January 2021

Plasmacytoid dendritic cells in immunity

1 reference

7 January 2021

Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist

1 reference

7 January 2021

Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis

1 reference

7 January 2021

Toll-like receptor 9-induced type I IFN protects mice from experimental colitis

1 reference

7 January 2021

Antigen-immunostimulatory oligonucleotide conjugates: mechanisms and applications

1 reference

7 January 2021

A controlled clinical trial comparing the safety and immunogenicity of a new adjuvanted hepatitis B vaccine with a standard hepatitis B vaccine

1 reference

7 January 2021

Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults

1 reference

7 January 2021

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

1 reference

7 January 2021

Cross-presentation: underlying mechanisms and role in immune surveillance

1 reference

7 January 2021

Combinatorial cancer immunotherapy

1 reference

7 January 2021

Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.

1 reference

7 January 2021

Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides

1 reference

7 January 2021

Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes

1 reference

7 January 2021

Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism

1 reference

7 January 2021

HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates

1 reference

7 January 2021

Toll-like receptor recognition regulates immunodominance in an antimicrobial CD4+ T cell response

1 reference

7 January 2021

On regulation of phagosome maturation and antigen presentation

1 reference

7 January 2021

Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer

1 reference

7 January 2021

Polymyxin B enhances ISS-mediated immune responses across multiple species

1 reference

7 January 2021

Toll-like receptor ligands: hygiene, atopy and therapeutic implications

1 reference

7 January 2021

Perspectives in asthma: molecular use of microbial products in asthma prevention and treatment

1 reference

7 January 2021

Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response

1 reference

7 January 2021

Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis

1 reference

7 January 2021

1 reference

7 January 2021

Immunoregulation by targeting T cells in the treatment of allergy and asthma

1 reference

7 January 2021

A restricted subset of dendritic cells captures airborne antigens and remains able to activate specific T cells long after antigen exposure

1 reference

7 January 2021

Immunostimulatory sequences regulate interferon-inducible genes but not allergic airway responses.

1 reference

7 January 2021

TLR7 ligand prevents allergen-induced airway hyperresponsiveness and eosinophilia in allergic asthma by a MYD88-dependent and MK2-independent pathway.

1 reference

7 January 2021

CpG oligodeoxynucleotides can reverse Th2-associated allergic airway responses and alter the B7.1/B7.2 expression in a murine model of asthma

1 reference

7 January 2021

CpG oligodeoxynucleotides do not require TH1 cytokines to prevent eosinophilic airway inflammation in a murine model of asthma☆☆☆★

1 reference

7 January 2021

Immunostimulatory oligonucleotides block allergic airway inflammation by inhibiting Th2 cell activation and IgE-mediated cytokine induction

1 reference

7 January 2021

Immunostimulatory oligonucleotides attenuate airways remodeling in allergic monkeys

1 reference

7 January 2021

Nonhuman primate models of asthma

1 reference

7 January 2021

CpG-oligodeoxynucleotides inhibit RSV-enhanced allergic sensitisation in guinea pigs.

1 reference

7 January 2021

Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells.

1 reference

7 January 2021

G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice

1 reference

7 January 2021

Immunotherapeutic uses of CpG oligodeoxynucleotides

1 reference

7 January 2021

Innate immunity for biodefense: a strategy whose time has come

1 reference

7 January 2021

Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis

1 reference

7 January 2021

HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells

1 reference

7 January 2021

Immune Interferon in the Circulation of Patients with Autoimmune Disease

1 reference

7 January 2021

Interferon and granulopoiesis signatures in systemic lupus erythematosus blood

1 reference

7 January 2021

Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus

1 reference

7 January 2021

TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity

1 reference

7 January 2021

Systemic lupus erythematosus and the type I interferon system

1 reference

7 January 2021

Autoimmunity to nucleosomes related to viral infection: a focus on hapten-carrier complex formation

1 reference

7 January 2021

Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells

1 reference

7 January 2021

Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA

1 reference

7 January 2021

Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus

1 reference

7 January 2021

Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9.

1 reference

7 January 2021

Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8.

1 reference

7 January 2021

Targeting Toll-like receptor signaling in plasmacytoid dendritic cells and autoreactive B cells as a therapy for lupus.

1 reference

7 January 2021

Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA.

1 reference

7 January 2021

Regulation of lung injury and repair by Toll-like receptors and hyaluronan

1 reference

7 January 2021

Emerging paradigm: toll-like receptor 4-sentinel for the detection of tissue damage.

1 reference

7 January 2021

Identifiers

DOI

10.1038/NM1589

1 reference

Dimensions Publication ID

16 August 2017

0 references

1 reference